Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRIVE: SR123781A for VTE prevention in total hip replacement
NCT00338897Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2006
- Primary completion
- May 2007
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of sr-123781a in venous thromboembolism (VTE) (6 arms), sponsored by Sanofi. Primary endpoint: Total Venous Thromboembolic Events at 10 days. Started May 2006; status: completed.
02
Drugs
sr-123781a
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00338897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00338897.